Perspective Therapeutics (FRA:AAJ0) EPS (Basic): €-1.20 (TTM As of Mar. 2026)


FRA:AAJ0 Perspective Therapeutics Inc FRA:AAJ0
31 GF Score
Price €2.56
! 1 Warning Sign
View Full Analysis

What is Perspective Therapeutics EPS (Basic)?

Perspective Therapeutics FRA:AAJ0 +3.72% 31 EPS (Basic) is €-1.20 as of Mar. 2026. GuruFocus rates FRA:AAJ0 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Perspective Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.22. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.20.

Perspective Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.20.

Perspective Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was €-0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.21.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Perspective Therapeutics  (FRA:AAJ0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Perspective Therapeutics EPS (Basic) Related Terms

Perspective Therapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics EPS (Basic) Chart

Perspective Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -0.47 -1.60 -1.18 -1.20

Perspective Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.25 -0.30 -0.44 -0.22
FRA:AAJ0
31GF Score
Perspective Therapeutics Inc FRA:AAJ0
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Perspective Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-88.065-0)/73.813
=-1.19

Perspective Therapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-22.653-0)/103.604
=-0.22

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-1.20 mean?
Perspective Therapeutics (FRA:AAJ0) has a EPS (Basic) of €-1.20 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Perspective Therapeutics and its competitors.
Is Perspective Therapeutics' EPS (Basic) too high?
Perspective Therapeutics' current EPS (Basic) is €-1.20. Overall, Perspective Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' EPS (Basic) compare to LAB and KIDS?
Perspective Therapeutics' EPS (Basic) of €-1.20 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Perspective Therapeutics and its competitors. Perspective Therapeutics's current EPS (Basic) is €-1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (FRA:AAJ0) has a current EPS (Basic) of €-1.20. The current EPS (Basic) is €-1.20. Perspective Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Perspective Therapeutics (FRA:AAJ0), the current EPS (Basic) is €-1.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges CATX:USA
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
31GF Score

Get the complete analysis for FRA:AAJ0

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price